Competitive Technologies to Exhibit Calmare(R) Pain Therapy Device at American Society of Clinical Oncology Annual Meeting June 3-7, 2011 | Bourse Reflex
Accueil > Actualités > Communiqués

Competitive Technologies to Exhibit Calmare(R) Pain Therapy Device at American Society of Clinical Oncology Annual Meeting June 3-7, 2011

Vendredi 03 Jun 2011 à 14:00

FAIRFIELD, Conn., June 2, 2011 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) announced today that its Calmare® pain therapy medical device featuring Scrambler Therapy technology will be exhibited at the American Society of Clinical Oncology (ASCO) Annual Meeting held at McCormick Place in Chicago, Illinois June 3-7, 2011. At the meeting, company representatives will showcase the Calmare device that clinical trials have shown to be effective in treating pain caused by cancer, especially chemotherapy induced peripheral neuropathy or CIPN.

The Calmare TEAM at Booth 2104 with the device will consist of Tim Conley, Calmare National Sales Manager; Frank Sparadeo, Ph.D., researcher and collaborator at Calmar Pain Relief; Jerry Stringham, President of Medical Technology Partners, reimbursement consultant; and Aris Despo, CTTC's Executive Vice President. View

"We are looking forward to sharing the Calmare device's clinical success in treating CIPN with doctors who are on the frontline in the battle against CIPN," said Mr. Despo. "While these medical professionals are treating cancer, they are also concerned about the negative side effects of the treatments they use to fight the spread of cancer. Our device offers them an effective treatment OPTION without side effects to help their patients suffering from CIPN. 

"We have seen a significant increase in interest in our non-invasive, drug-free therapy following the publication in December 2010 of results from the study completed by Dr. Thomas Smith, M.D. and others from the VCU Massey Cancer Center. Additional studies of the Calmare device's efficacy in treating CIPN, cancer-related pain and other types of neuropathic pain are underway at VCU Massey, as well as the University of Wisconsin, Madison and at the Mayo Clinic." 

About Competitive Technologies, Inc

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions. Competitive Technologies was established in 1968.

 CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical Scrambler Therapy technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. The Calmare device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit Visit CTTC's website:

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: Jean Wilczynski, IR Services, LLC
(860.434.2465 /


Partager sur Facebook
Article Précédent :
Apricus Biosciences Appoints Steve...
Article Suivant :
Apricus Bio CEO to Present...

Ecrire un commentaire

J'accepte la charte et que mon commentaire soit publié sur 

Les autres actualités

Retour vers 'Communiqués' »

Mots-clés : Pain   Device   Society   Clinical   Oncology   June   Cttc   Technology   Cipn   Sales   Despo   Looking   They   Side   Invasive   Massey   Neuropathic  
Sociétés citées dans cette news : Option   TEAM   MADE  

Si vous passez un ordre de bourse sur le CAC40 le vendredi soir à 18h, quand sera t-il éxécuté?